DVA vs IMTX: fair value comparison
DaVita Inc. and Immatics N.V. · Updated 2026-10-19
IMTX reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, DVA currently ranks higher by quality score.
| DVA | IMTX | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $179.25 | $8.44 |
| 12-month range | $103.87–$240.96 | $6.73–$11.87 |
| Rank by discount to fair value | #29 of 108 Healthcare | — |
| Rank by quality score | #100 of 301 Healthcare | #102 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: DVA fair value analysis · IMTX fair value analysis